Goldman Sachs upgrades Innoviz stock rating to Buy on design win potential

Goldman Sachs upgraded Innoviz Technologies (INVZ) to Buy with a $2.50 price target, citing the company's strong design win potential, relative valuation, and strategic OEM partnerships, including a recent win with a major Class 8 trucking OEM. This upgrade, projecting 129% revenue growth for FY2025, acknowledges a recent Q2 2025 revenue miss and rapid cash burn, yet anticipates a path to positive EBITDA by 2028 contingent on successful program execution and design conversions.

Analysis

Goldman Sachs has upgraded Innoviz Technologies (INVZ) to Buy from Neutral, increasing its price target to $2.50, which implies a 47% upside from the current price. The upgrade is predicated on anticipated design wins within the next 3-6 months and a favorable valuation relative to lidar industry peers. This positive outlook is supported by the company's established partnerships, including programs with Volkswagen, Mobileye, a top-five global passenger auto OEM, and a recent agreement to supply a Class 8 trucking OEM for SAE Level 4 autonomous vehicles. Despite a strong stock performance with a 158% return over the past six months, there are notable risks. The company is rapidly burning through its cash reserves and reported a revenue miss for Q2 2025, with revenues of $9.75 million against a forecast of $10.75 million, although EPS met expectations at -$0.09. The long-term bull case hinges on execution, with analysts forecasting 129% revenue growth for FY2025 and a potential path to positive EBITDA by 2028, contingent on securing further series production awards and achieving meaningful volume with existing partners.

Key Decisions for Investors

• Given the Goldman Sachs upgrade and strong design win pipeline, investors may view the current valuation as an attractive entry point for exposure to the autonomous vehicle technology sector, especially considering the stock trades at a discount to peers.
• Investors must closely monitor the company's cash burn rate and its ability to convert its development pipeline into committed series production awards over the next two quarters, as failure to do so presents the primary downside risk to the investment thesis.
• While the long-term growth narrative is compelling, the recent Q2 2025 revenue miss highlights near-term execution risk, suggesting that positions should be managed with an awareness of potential volatility around future contract announcements and quarterly earnings reports.